Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

被引:17
作者
Giambra, Vincenzo [1 ]
Piazzolla, Annarita Valeria [2 ]
Cocomazzi, Giovanna [2 ]
Squillante, Maria Maddalena [2 ]
De Santis, Elisabetta [1 ]
Totti, Beatrice [1 ]
Cavorsi, Chiara [2 ]
Giuliani, Francesco [3 ]
Serra, Nicola [4 ]
Mangia, Alessandra [2 ]
机构
[1] Fdn IRCCS Casa Sollievo Sofferenza, Inst Stem Cell Biol Regenerat Med & Innovat Thera, I-71013 San Giovanni Rotondo, Italy
[2] Fdn IRCCS Osped Casa Sollievo Sofferenza, Liver Unit, I-71013 San Giovanni Rotondo, Italy
[3] Fdn IRCCS Osped Casa Sollievo Sofferenza, ICT Innovat & Res Unit, I-71013 San Giovanni Rotondo, Italy
[4] Univ Federico II, Dept Publ Hlth, I-80138 Naples, Italy
关键词
liver cirrhosis; SARS-CoV-2; mRNA vaccine; MELD score; COVID-19; VACCINES; LIVER-DISEASE;
D O I
10.3390/vaccines10081281
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunoresponses of patients with LC after two or three doses of the mRNA Pfizer-BioNTech vaccine against SARS-CoV-2 and to investigate clinical features associated with non-response. Material and methods: 179 patients with LC of CTP class A in 93.3% and viral etiology in 70.1% of cases were longitudinally evaluated starting from the day before the first dose to 4 weeks after the booster dose. Their antibody responses were compared to those of healthcare workers without co-morbidities. In a subgroup of 40 patients, B- and T-cell responses were also compared to controls. Results: At d31, d90 and d180 after BNT162b2 vaccine, no detectable SARS-CoV-2 IgG response was observed in 5.9%, 3.9% and 7.2% of LC patients as compared to 0 controls (p < 0.03). A delay in B-cell and lack of prompt T-cell response compared to healthcare workers was also registered. A significant correlation between antibody titers and cellular response was observed. A MELD score > 8 was the only independent predictor of poor d31 response (p = 0.028). Conclusions: Our results suggest that cirrhotic patients have a slower and in <10% suboptimal immune response to SARS-CoV-2 vaccination. Rates of breakthrough infections were comparable between cirrhotics and controls. The booster dose was critical in inducing both humoral and cellular responses comparable to controls.
引用
收藏
页数:13
相关论文
共 33 条
[1]   Response to hepatitis B vaccination in patients with liver cirrhosis [J].
Aggeletopoulou, Ioanna ;
Davoulou, Panagiota ;
Konstantakis, Christos ;
Thomopoulos, Konstantinos ;
Triantos, Christos .
REVIEWS IN MEDICAL VIROLOGY, 2017, 27 (06)
[2]   Protection against the Omicron Variant from Previous SARS-CoV-2 Infection [J].
Altarawneh, Heba N. ;
Chemaitelly, Hiam ;
Hasan, Mohammad R. ;
Ayoub, Houssein H. ;
Qassim, Suelen ;
AlMukdad, Sawsan ;
Coyle, Peter ;
Yassine, Hadi M. ;
Al-Khatib, Hebah A. ;
Benslimane, Fatiha M. ;
Al-Kanaani, Zaina ;
Al-Kuwari, Einas ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar H. ;
Latif, Ali N. ;
Shaik, Riyazuddin M. ;
Abdul-Rahim, Hanan F. ;
Nasrallah, Gheyath K. ;
Al-Kuwari, Mohamed G. ;
Butt, Adeel A. ;
Al-Romaihi, Hamad E. ;
Al-Thani, Mohamed H. ;
Al-Khal, Abdullatif ;
Bertollini, Roberto ;
Tang, Patrick ;
Abu-Raddad, Laith J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (13) :1288-1290
[3]   Vaccination in Chronic Liver Disease: An Update [J].
Alukal, Joseph J. ;
Naqvi, Haider A. ;
Thuluvath, Paul J. .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (03) :937-947
[4]  
[Anonymous], NATL COVID 19 VACCIN
[5]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[6]   Covid-19 Breakthrough Infections in Vaccinated Health Care Workers [J].
Bergwerk, Moriah ;
Gonen, Tal ;
Lustig, Yaniv ;
Amit, Sharon ;
Lipsitch, Marc ;
Cohen, Carmit ;
Mandelboim, Michal ;
Gal Levin, Einav ;
Rubin, Carmit ;
Indenbaum, Victoria ;
Tal, Ilana ;
Zavitan, Malka ;
Zuckerman, Neta ;
Bar-Chaim, Adina ;
Kreiss, Yitshak ;
Regev-Yochay, Gili .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1474-1484
[7]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594
[8]  
CDC, FRAM BOOST DOS COVID
[9]   Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 [J].
Chan, Kui K. ;
Dorosky, Danielle ;
Sharma, Preeti ;
Abbasi, Shawn A. ;
Dye, John M. ;
Kranz, David M. ;
Herbert, Andrew S. ;
Procko, Erik .
SCIENCE, 2020, 369 (6508) :1261-+
[10]   One Year of COVID-19 Vaccines A Shot of Hope, a Dose of Reality [J].
Cohn, Amanda C. ;
Mahon, Barbara E. ;
Walensky, Rochelle P. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (02) :119-120